
Objective To determine how MRI-based exclusion of selected structural pathologies and cartilage damage thresholds affect recruitment and responsiveness of cartilage thickness decline in a clinical trial cohort with advanced radiographic knee osteoarthritis. Method This post-hoc analysis included the 200 placebo-arm participants of the ROCCELLA trial, all with medial joint space narrowing OARSI grade 1 or 2. Rapid OsteoArthritis MRI Eligibility Score (ROAMES)-type exclusions were applied; MOAKS was mapped to corresponding WORMS cartilage scores to facilitate interpretation. 12-month central medial femorotibial cartilage thickness change was analyzed by expert segmentation; responsiveness was expressed as standardized response mean (SRM). Results Thirty-six of 200 participants (18%) had an exclusionary finding according to ROAMES criteria, including 28 meniscal root tears. Among 188 participants with 12-month MRI, the mean cartilage loss was −113 μm (SRM -0.43); it was −131 μm (SRM -0.41) with and −109 μm (SRM -0.44) in the absence of exclusionary findings. Among 154 knees without exclusionary findings but with MRI, 91 had medial femorotibial WORMS≥5. These showed a −133 μm loss (SRM -0.50), compared with −74 μm (SRM -0.35) in 63 WORMS<5 knees. Excluding WORMS≥5 anywhere in the knee left 46 knees, with −86 μm loss (SRM −0.38); 10 knees with WORMS = 6 showed −154 μm loss (SRM -0.77). Conclusion MRI screening identified ROAMES-type pathologies in a substantial proportion of radiographically eligible participants and their exclusion minimally affected cartilage thickness responsiveness. Excluding advanced cartilage damage, however, substantially reduced amounts and sensitivity to cartilage thickness decline. Recruitment, measurement performance, and treatment-response assumptions must be considered when defining MRI eligibility criteria.
Objective To quantify excess healthcare use attributable to incident depression and anxiety in people with osteoarthritis (OA). Methods A matched register-based cohort study. Individuals aged 40+ residing in Skåne in 2009 with an OA diagnosis during 1998–2009 and a first diagnosis or medication dispensation for depression (n = 8125) or anxiety (n = 9545) during 2010–2018 were defined as cases. These were matched to up to 4 controls by birth year, sex and follow-up time. We measured healthcare consultations (HCCs) and defined daily dose (DDD) of all medications at 3-month intervals and hospital inpatient days at 1-year intervals from 3 years before to 3 years after the index date (depression/anxiety diagnosis date). We used two-part models to estimate excess healthcare use attributable to depression/anxiety. Results Persons with depression/anxiety had higher healthcare uses than their matched controls throughout the observation period. The greatest differences were observed in the quarter after diagnosis for HCCs and medication, and the year before diagnosis for inpatient days. Over 6-year observation period, persons with depression/anxiety had, on average, 46 (95% CI: 45, 48)/46 (44, 47) more HCCs, 3306 (3 112, 3501)/2768 (2 590, 2946) more DDD of medications, and 13 (12, 14)/14 (13, 15) more inpatient days than their matched controls. Conclusion Among OA patients, those with depression/anxiety had more healthcare use from three years before to three years after diagnosis than controls, suggesting possible delay in the diagnosis and management of depression/anxiety and the need for improved care.
Objective To critically reassess low-dose radiotherapy (LDRT) in patients with osteoarthritis (OA) across the full translational pathway, from biological rationale to clinical efficacy and the requirements for definitive evaluation. Methods This multidisciplinary narrative review appraised mechanistic, preclinical and clinical evidence for LDRT in OA, with particular emphasis on the translational relevance of experimental models and on randomized evidence, especially sham-controlled trials. Recent technical consensus, safety assessments and OA trial-methodology literature were also considered. Results Preclinical studies support context-dependent immunomodulatory effects of LDRT involving endothelial–leukocyte interactions, immune-cell activation and joint-tissue crosstalk, but much of this evidence derives from reductionist or inflammatory models rather than chronic human OA. OA-specific experimental evidence remains limited. Clinically, two sham-controlled trials using 6 × 1 Gy were negative, whereas more recent studies using 6 × 0.5 Gy have reported positive signals that remain preliminary or methodologically limited. No responder phenotype has been validated. A definitive evaluation should therefore integrate clinically meaningful pain and/or functional impairment despite optimized standard OA care, prospective evaluation of inflammatory or imaging-based enrichment, biological target-engagement measures, standardized radiation delivery, rigorous sham-controlled OA outcomes, long-term safety, and assessment of clinical and health-system feasibility. Conclusion There is a biological rationale for LDRT in OA, but current evidence remains insufficient to support routine use in patients with OA. Its future role should be defined through adequately powered, phenotype-informed sham-controlled trials conducted jointly by OA and radiation experts.